TCG Crossover Management, LLC
- SEC CIK
- 0001839948
- Latest filing
- Aug 14, 2026
Holdings in Q3 2022
Holdings as of Sep 30, 2022, filed Nov 14, 2022. Long positions only; changes compare share counts with Q2 2022.
- Positions
- 21
- −1 vs. Q2 2022
- Portfolio value
- $333.4M
- +$98.0M (+41.6%) vs. Q2 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| ISEEIVERIC bio, Inc. | COM | 3,877,903 | $69.6M | 20.9% | +963,653+33.1% | Added | History |
| COGTCogent Biosciences, Inc. | COM | 3,481,042 | $51.9M | 15.6% | 00.0% | Unchanged | History |
| GERNGeron Corp | COM | 12,115,926 | $28.4M | 8.5% | −2,980,416−19.7% | Reduced | History |
| VRDNViridian Therapeutics, Inc. | COM | 1,164,000 | $23.9M | 7.2% | −150,000−11.4% | Reduced | History |
| SLNSilence Therapeutics plc | ADS | 2,104,875 | $21.1M | 6.3% | +2,104,875 | New | History |
| CBAYCymaBay Therapeutics, Inc. | COM | 5,905,400 | $20.7M | 6.2% | 00.0% | Unchanged | History |
| KURAKura Oncology, Inc. | COM | 1,348,642 | $18.4M | 5.5% | +181,000+15.5% | Added | History |
| ACRSAclaris Therapeutics, Inc. | COM | 1,144,939 | $18.0M | 5.4% | 00.0% | Unchanged | History |
| JBIOJade Biosciences, Inc. | COM | 959,572 | $15.9M | 4.8% | +70,000+7.9% | Added | History |
| TRDAEntrada Therapeutics, Inc. | COM | 642,189 | $10.1M | 3.0% | −21,505−3.2% | Reduced | History |
| ALLKAllakos Inc. | COM | 1,643,500 | $10.1M | 3.0% | +1,643,500 | New | History |
| AKUSAkouos, Inc. | COM | 1,350,006 | $9.13M | 2.7% | 00.0% | Unchanged | History |
| TYRATyra Biosciences, Inc. | COM | 945,707 | $8.31M | 2.5% | +49,289+5.5% | Added | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 1,000,000 | $7.76M | 2.3% | 00.0% | Unchanged | History |
| MRUSMerus N.V. | COM | 300,000 | $6.01M | 1.8% | 00.0% | Unchanged | History |
| TNGXTango Therapeutics, Inc. | COM | 1,172,250 | $4.24M | 1.3% | 00.0% | Unchanged | History |
| DNTHDianthus Therapeutics, Inc. | COM | 2,124,122 | $3.00M | 0.9% | 00.0% | Unchanged | History |
| ZLABZai Lab Ltd | ADR | 72,777 | $2.49M | 0.7% | −22,223−23.4% | Reduced | History |
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 30,000 | $1.95M | 0.6% | +30,000 | New | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 254,569 | $1.83M | 0.5% | −323,691−56.0% | Reduced | History |
| ELEVElevation Acquisition Group Inc. | COM | 555,000 | $627.0K | 0.2% | 00.0% | Unchanged | History |
Sold out since Q2 2022 (4)
Positions held at the end of Q2 2022 that are gone from this filing.
| Security | Class | Shares in Q2 2022 | Value in Q2 2022 | % of portfolio in Q2 2022 | History |
|---|---|---|---|---|---|
| KDNYChinook Therapeutics, Inc. | COM | 796,460 | $13.9M | 5.9% | History |
| ETNB89bio, Inc. | COM | 1,133,196 | $3.65M | 1.6% | History |
| ANABAnaptysbio, Inc | COM | 58,515 | $1.19M | 0.5% | History |
| PRDSPardes Biosciences, Inc. | COM | 59,039 | $181.0K | 0.1% | History |